Research programme: HCV protease inhibitors - GenoscienceAlternative Names: BL-8030; GNS 037; GNS 37; HCV NS3-4A PI - Genoscience; HCV protease inhibitors - RFS Pharma/Genoscience
Latest Information Update: 12 Jun 2013
At a glance
- Originator Genoscience; RFS Pharma LLC - Genoscience (JV)
- Developer Genoscience
- Class Peptides
- Mechanism of Action Hepatitis C protease inhibitors; Hepatitis C virus NS3 protein inhibitors; HIV fusion inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hepatitis C
- Discontinued HIV infections